Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 12/20 | 0.60 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.60 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341444 | 1.00 | LPAR1 (0.60) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL341799 | 0.96 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL341798 | 0.96 | LPAR1 (0.59) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL342326 | 0.96 | LPAR1 (0.58) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2780894 | 0.89 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2781710 | 0.89 | LPAR1 (0.62) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL2781714 | 0.89 | LPAR1 (0.62) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL343416 | 0.89 | LPAR1 (0.75) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL342948 | 0.89 | LPAR1 (0.75) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL342949 | 0.89 | LPAR1 (0.75) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438048-B1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8273780-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 2717/4885ABCC4 2854/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 2717/4885ABCC4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.